TY  - JOUR
AU  - Richardson, Tim
AU  - Mai, Elias
AU  - Menis, Ekaterina
AU  - Benner, Axel
AU  - Tichy, Diana
AU  - Miah, Kaya
AU  - Hänel, Mathias
AU  - Besemer, Britta
AU  - Boquoi, Amelie
AU  - Blau, Igor Wolfgang
AU  - Michel, Christian S
AU  - Lindemann, Hans Walter
AU  - Janjetovic, Snjezana
AU  - Brossart, Peter
AU  - Bernhard, Helga
AU  - Reimer, Peter
AU  - Salwender, Hans
AU  - Hose, Dirk
AU  - Seckinger, Anja
AU  - Raab, Marc
AU  - Goldschmidt, Hartmut
AU  - Scheid, Christof
TI  - Prognostic Impact of the Hevylite Assay in Patients With IgG or IgA Multiple Myeloma Treated Within the GMMG-MM5 Trial.
JO  - European journal of haematology
VL  - nn
SN  - 0902-4441
CY  - Oxford
PB  - Wiley-Blackwell
M1  - DKFZ-2025-02376
SP  - nn
PY  - 2025
N1  - epub
AB  - Response assessment during treatment of multiple myeloma (MM) typically relies on immunofixation and serum electrophoresis. However, low levels of IgG and especially IgA paraprotein are difficult to quantify reliably. The Hevylite Assay quantifies the kappa and lambda fractions of IgG and IgA separately and is useful to determine response to therapy. Using serum samples of 360 evaluable patients from the prospective GMMG-MM5 trial (EudraCT-No. 2010-019173-16) we assessed the normalization of the kappa/lambda ratio with the Hevylite Assay (HLCr) at baseline, after induction, mobilization, autologous blood stem cell transplantation, consolidation and every three months during maintenance or follow-up within two years after the end of consolidation. We observed a steady increase in the proportion of patients with normalized HLCr over the course of therapyAchieving HLCr normalization any time until the end of consolidation was associated with a trend towards a prolonged progression-free survival (PFS; hazard ratio (HR) = 0.75, 95
KW  - heavylite assay (Other)
KW  - multiple myeloma (Other)
KW  - prognostic biomarker (Other)
LB  - PUB:(DE-HGF)16
C6  - pmid:41216847
DO  - DOI:10.1111/ejh.70061
UR  - https://inrepo02.dkfz.de/record/305756
ER  -